Fredun Pharmaceuticals Shows Strong Growth Amid Shift to Mildly Bullish Trend

Fredun Pharmaceuticals, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape surrounding the stock, indicating a transition from a bullish to a mildly bullish technical trend.
Key financial metrics reveal that Fredun Pharmaceuticals has demonstrated robust growth, with net sales increasing at an annual rate of 32.11% and operating profit rising by 49.33%. The company has consistently reported positive results over the last four quarters, with net sales reaching a peak of Rs 167.41 crore and a PBT less other income of Rs 8.04 crore, which has grown at 37.67%.

The stock is currently trading at a discount compared to its peers' average historical valuations, supported by a return of 10.05% over the past year and a profit increase of 33.2%. With a return on capital employed (ROCE) of 16.8 and a PEG ratio of 0.6, Fredun Pharmaceuticals maintains an attractive valuation profile.

For more insights on Fredun Pharmaceuticals and its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.